BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

Leukemia

Volumn 28, Issue 3, 2014, Pages 649-657

  Cheng, S ^a   Ma, J ^a   Guo, A ^a   Lu, P ^a   Leonard, J P ^a   Coleman, M ^a   Liu, M ^a   Buggy, J J ^b   Furman, R R ^a   Wang, Y L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

BCR pathway; BTK; ibrutinib; In vivo CLL proliferation; PCI 32765

Indexed keywords

BROXURIDINE; BRUTON TYROSINE KINASE; IBRUTINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE B;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MALE; MIDDLE AGED; PRIORITY JOURNAL; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84895785316     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.358     Document Type: Article

References (48)

1. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262.
2. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
3. Deng C, Lee S, O'Connor OA. New strategies in the treatment of mantle cell lymphoma. Clin Cancer Res 2012; 18: 3499-3508.
4. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 2006; 108: 3135-3142.
5. Widhopf 2nd GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004; 104: 2499-2504.
6. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
7. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
8. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004; 41: 599-613.
9. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol 2009; 28: 21-55.
10. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol 2010; 28: 185-210.
11. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008; 112: 1443-1452.
12. Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008; 143: 698-706.
13. Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: Molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008; 22: 1755-1766.
14. Lu P, Yang C, Guasparri I, Harrington W, Wang YL, Cesarman E. Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. Leukemia 2009; 23: 807-810.
15. Song Z, Lu P, Furman RR, Leonard JP, Martin P, Tyrell L et al. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin Cancer Res 2010; 16: 587-599.
16. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011; 153: 199-211.
17. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230-2237.
18. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011; 118: 6342-6352.
19. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-1037.
20. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, Sica S et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686-697.
21. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-4506.
22. Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010; 116: 4894-4905.
23. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088.
24. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
25. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010; 116: 1460-1468.
26. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
27. Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011; 17: 2977-2986.
28. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
29. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson Jr DM, Wagner-Johnston ND et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-Kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2010; 116: 55.
30. Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Meeting Abstracts 2011; 29(15-suppl): 6631.
31. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
32. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-13080.
33. Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts 2011; 29(15-suppl): 6508.
34. Serpa M, Bendit I, Seguro F, Xavier F, Cavalcante M, Steinbaum D et al. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia. Acta Haematol 2010; 124: 105-109.
35. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 2820-2822.
36. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
37. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-2594.
38. Smith MA, Houghton P. A proposal regarding reporting of in vitro testing results. Clin Cancer Res 2013; 19: 2828-2833.
39. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: Development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009; 114: 4441-4450.
40. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296.
41. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
42. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111: 846-855.
43. Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 2013; 27: 2311-2321.
44. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009; 114: 4832-4842.
45. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: Are we getting closer to understanding the pathogenesis of the disease?. J Clin Oncol 2008; 26: 4497-4503.
46. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755-764.
47. Plander M, Seegers S, Ugocsai P, Diermeier-Daucher S, Ivanyi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118-2128.
48. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352-3359..